Novo Nordisk A/S (NVO) shares dropped 5.7% during early trading on Wednesday. The company forecasts a 5% to 13% decrease in both sales and operating profit for 2026, as it confronts pricing pressures in the United States and patent expirations in non-U.S. markets, despite favorable progress with the oral version of Wegovy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.